Lilly's $3B Investment to Expand Wisconsin Plant for Zepbound and Mounjaro

Eli Lilly has strategically pledged a $3 billion investment to expand its manufacturing facility in Kenosha County, Wisconsin, marking it as the company's largest U.S. manufacturing site outside of Indiana. This expansion is aimed at bolstering the production of injectable medications, particularly to meet the escalating demand for Lilly's leading weight loss and diabetes treatments, Zepbound and Mounjaro[1]. The project, commencing construction next year, will introduce 750 permanent jobs while employing over 2,000 construction workers, facilitated by advanced automation technologies to boost efficiency and precision[2]. This endeavor reflects Lilly's broader $23 billion commitment since 2020 toward scaling up its global manufacturing capabilities in response to intense competition from Novo Nordisk and the booming demand for GLP-1 therapies[1].